The Use of Rivaroxaban in?Patients With Atrial Fibrillation Receiving Hemodialysis-Antithrombotic Therapy for Atrial Fibrillation: CHEST Guideline and Expert Panel?Report

摘要

Thank you for your time and dedication to the development of the guidelines by Lip et?alsup1/sup in a previous issue of CHEST (November 2018). I would like to take this moment to bring to your attention an error in the aforementioned publication. Specifically, a remark made in recommendation 54 (end-stage renal disease [ESRD]), which states “NOACs [novel oral anticoagulants] should generally not be used, although in USA, apixaban 5mg bid is approved for use in AF patients receiving hemodialysis.” This statement is not accurate.